Managing Plexiform Neurofibroma and Other Complications of Neurofibromatosis Type 1 in the Adult Neurology Clinic
5 affiliations
- 1NYU Langone Health, New York, NY
- 2The University of Alabama at Birmingham
- 3Dartmouth Hitchcock Medical Center, Lebanon, NH
- 4University of California, San Diego, La Jolla; and
- 5Woven Health Collective, New York.
Abstract
Purpose of Review: Loss-of-function variants in the NF1 gene result in the development of neurofibromatosis type 1 (NF1), a neurogenetic disease and multisystem disorder that includes a predilection for benign and malignant tumors of the central and peripheral nervous systems. Patients with NF1 experience a wide variety of comorbidities, such as chronic pain conditions, learning disabilities, and signs and symptoms that include migraines and NF1-associated plexiform neurofibromas (PNs), which can cause disfigurement and pain. All of these factors can severely affect health-related quality of life (HRQoL). Although treatment options are limited, advances in targeted therapies have led to the approval of the mitogen-activated protein kinase kinase 1 and 2 (MEK1/2) inhibitors selumetinib and mirdametinib, which reduce target PN volume and improve HRQoL in patients with NF1-PNs.
Recent Findings: A multidisciplinary team is necessary to evaluate patients and determine appropriate treatments that may reduce the burden of NF1. For adult patients with NF1, neurologists or neuro-oncologists may determine individual patient imaging and serial monitoring needs based on clinical evaluations and patient history. Imaging is useful to identify and determine the extent of potentially concerning tumors, although the specific imaging methods available depend on individual institutional capabilities. Biopsies may be conducted on areas of clinical or radiologic concern to determine the presence of malignant peripheral nerve sheath tumors or atypical neurofibromatous neoplasm of uncertain biological potential. Systemic treatment or surgical debulking may be recommended to reduce PN symptoms caused by tumor size, inflammation, and compression of vital organs. However, in patients with inoperable symptomatic NF1-PN, systemic MEK inhibitors may be considered to target PN volume reductions. Currently, 2 MEK1/2 inhibitors (selumetinib and mirdametinib) are approved by the US Food and Drug Administration and European Commission for the treatment of NF1-PN.
Summary: Because of the complexity of how and when to administer treatment and the impact of symptoms on HRQoL, a multidisciplinary team is essential to manage the manifestations of NF1, including PN, to achieve the greatest benefit from currently available therapies.
Related
- A Plexiform Neurofibroma Mimicking a Lipoma: A Rare Case.
- Unmasking neurofibromatosis type 1 with the discovery of a renal neurofibroma
- Giant Cervicothoracic Ganglioneuroma Misdiagnosed as Neurofibroma on Core Needle Biopsy: Transcervical Resection and Postoperative Neurological Sequelae: A Case Report
- Visor Flap-Assisted Segmental Mandibulectomy and Immediate Free Fibula Reconstruction for Extensive Plexiform Ameloblastoma of the Anterior Mandible: A Case Report
- Fibromixoma plexiforme gástrico como desafío diagnóstico frente a un GIST Gastric Plexiform Fibromyxoma as a Diagnostic Challenge in the Differential Diagnosis of GIST
BibTeX
@article{schulte2026managing,
title = {{Managing Plexiform Neurofibroma and Other Complications of Neurofibromatosis Type 1 in the Adult Neurology Clinic}},
author = {Jessica Schulte and Rebecca M. Brown and Nupur Lala and Nikhil K. Murthy and G. Praveen Raju and Jonathan Andrew Mitchell and Kaleb Yohay},
journal = {Neurology: Clinical Practice},
year = {2026},
month = oct,
doi = {10.1212/cpj.0000000000200662},
url = {https://doi.org/10.1212/cpj.0000000000200662},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Managing Plexiform Neurofibroma and Other Complications of Neurofibromatosis Type 1 in the Adult Neurology Clinic
AU - Jessica Schulte
AU - Rebecca M. Brown
AU - Nupur Lala
AU - Nikhil K. Murthy
AU - G. Praveen Raju
AU - Jonathan Andrew Mitchell
AU - Kaleb Yohay
PY - 2026
DA - 2026/10/23
JO - Neurology: Clinical Practice
DO - 10.1212/cpj.0000000000200662
UR - https://doi.org/10.1212/cpj.0000000000200662
AB - Purpose of Review: Loss-of-function variants in the NF1 gene result in the development of neurofibromatosis type 1 (NF1), a neurogenetic disease and multisystem disorder that includes a predilection for benign and malignant tumors of the central and peripheral nervous systems. Patients with NF1 experience a wide variety of comorbidities, such as chronic pain conditions, learning disabilities, and signs and symptoms that include migraines and NF1-associated plexiform neurofibromas (PNs), which can cause disfigurement and pain. All of these factors can severely affect health-related quality of life (HRQoL). Although treatment options are limited, advances in targeted therapies have led to the approval of the mitogen-activated protein kinase kinase 1 and 2 (MEK1/2) inhibitors selumetinib and mirdametinib, which reduce target PN volume and improve HRQoL in patients with NF1-PNs. Recent Findings: A multidisciplinary team is necessary to evaluate patients and determine appropriate treatments that may reduce the burden of NF1. For adult patients with NF1, neurologists or neuro-oncologists may determine individual patient imaging and serial monitoring needs based on clinical evaluations and patient history. Imaging is useful to identify and determine the extent of potentially concerning tumors, although the specific imaging methods available depend on individual institutional capabilities. Biopsies may be conducted on areas of clinical or radiologic concern to determine the presence of malignant peripheral nerve sheath tumors or atypical neurofibromatous neoplasm of uncertain biological potential. Systemic treatment or surgical debulking may be recommended to reduce PN symptoms caused by tumor size, inflammation, and compression of vital organs. However, in patients with inoperable symptomatic NF1-PN, systemic MEK inhibitors may be considered to target PN volume reductions. Currently, 2 MEK1/2 inhibitors (selumetinib and mirdametinib) are approved by the US Food and Drug Administration and European Commission for the treatment of NF1-PN. Summary: Because of the complexity of how and when to administer treatment and the impact of symptoms on HRQoL, a multidisciplinary team is essential to manage the manifestations of NF1, including PN, to achieve the greatest benefit from currently available therapies.
SN - 2163-0402
SN - 2163-0933
ER -